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The intestinal epithelium constitutes an efficient
barrier against the microbial flora. Here, we demon-
strate an unexpected function of IL-33 as a regu-
lator of epithelial barrier functions. Mice lacking
IL-33 showed decreased Paneth cell numbers and
lethal systemic infection in response to Salmonella
typhimurium. IL-33 was produced upon microbial
challenge by a distinct population of pericryptal
fibroblasts neighboring the intestinal stem cell niche.
IL-33 programmed the differentiation of epithelial
progenitors toward secretory IEC including Paneth
and goblet cells. Finally, IL-33 suppressed Notch
signaling in epithelial cells and induced expression
of transcription factors governing differentiation
into secretory IEC. In summary, we demonstrate
that gut pericryptal fibroblasts release IL-33 to trans-
late bacterial infection into an epithelial response to
promote antimicrobial defense.INTRODUCTION
Interleukin 33 (IL-33) is an IL-1-like cytokine acting both as a
conventional cytokine through activation of the ST2 cell surface
receptor complex and as an intracellular nuclear factor with tran-
scription-factor-like properties (Haraldsen et al., 2009). Depend-
ing on the physiological context, IL-33 has been described to be
host protective or pathogenic in humans andmice (Bamias et al.,
2012; Lopetuso et al., 2013). IL-33 is expressed in many cell
types like endothelial, bone-marrow-derived dendritic cells,
epithelial cells, and synovial fibroblasts (Oboki et al., 2010). It
has been demonstrated to act as a signaling molecule with
dichotomous functions in the gut. Where on the one hand it
is able to activate many cells of the immune system, notably eo-
sinophils and type 2 innate lymphoid cells to drive inflammation,
on the other hand, it has been demonstrated to promote epithe-
lial integrity (Pastorelli et al., 2013; Polumuri et al., 2012). InCel
This is an open access article under the CC BY-Nrecent years, IL-33 has emerged as a classical activator of
type 2 immunity along with cytokines such as IL-4, IL-9, and
IL-13 (Pastorelli et al., 2013; Schmitz et al., 2005). Besides its as-
sociation with multiple diseases including asthma, fibrosis, and
dermatitis, the IL-33/ST2 axis has also been shown to be vital
in gut-related disorders like ulcerative colitis (UC) and Crohn’s
disease (Beltra´n et al., 2010; Kobori et al., 2010; Pastorelli
et al., 2010; Sedhom et al., 2013). However, the detailed func-
tional role of IL-33 as a signaling molecule in the intestine is still
in ambiguity.
Intestinal stem cells, like LGR5+ crypt base columnar cells
(CBCs), are responsible for maintaining differentiated cells,
which are broadly classified into two distinct lineages: absorp-
tive enterocytes and cells of the secretory type (Gracz and
Magness, 2014). It has been established that the master tran-
scriptional regulators Hes1 and Math1 can guide the stem cell
in committing to either of these cell types (Yang et al., 2001).
Secretory cells like Paneth, goblet, and enteroendocrine (EE)
cells have specific immune and tissue regulatory functions
such as secretion of antimicrobial peptides (AMPs), mucus pro-
duction, andmaintenance of gut-hormonal balance, respectively
(Vereecke et al., 2011). Perturbations in these crucial functions
lead to barrier defects and increased bacterial translocation.
Cell intrinsic signaling like Notch ensures integrity in the intes-
tinal epithelium by controlling early differentiation markers such
as Hes1 and Math1 (Obata et al., 2012). Inhibition of the Notch-
signaling pathway has been associatedwith goblet cell hyperpla-
sia (Fre et al., 2005). Goblet cell expansion in parasite-infected
models has been attributed to IL-33 (Humphreys et al., 2008).
Additionally, the expression of the Notch ligands Dll1 and Dll4 is
vital for intestinal homeostasis and maintenance of stem cells
(Pellegrinet et al., 2011; VanDussen et al., 2012). A recent study
has indicated a regulation of the Notch ligands Jag1, Dll1, and
Dll4 in IL-33-treated animals during chemically induced colonic
inflammation (Imaeda et al., 2011). In contrast, another report
demonstrated that Notch signaling is upstream of IL-33 expres-
sion in cultured endothelial cells (Sundlisaeter et al., 2012).
Collectively, IL-33 is a highly pleiotropic cytokine. Its regulation
and function in the gut is currently not well understood andmight
depend on the target cell and the immunological challenge.l Reports 15, 1743–1756, May 24, 2016 ª 2016 The Author(s) 1743
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. IL-33/ Mice Are Highly Susceptible to Salmonella Typhimurium Infection
(A) In vivo imaging of IL-33+/ and IL-33/mice orally infected with bioluminescent S. Typhimurium for 5 days. Graph depicts quantification of bioluminescence
signals measured as counts/s/cm2/sr (n = 5; mean ± SD).
(B) Representative pictures of H&E stainings of ileum and caecum cross-sections of IL-33+/ and IL-33/mice after infection (scale bars represent 100 mm and
200 mm).
(C) Histological scoring of tissue damage in the caecum of infected animals (n = 5; mean ± SD) and ileal Paneth cell (PC) counts (n = 5; mean ± SD).
(legend continued on next page)
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We now describe that IL-33 directly influences intestinal stem
cells in a ST2-dependent manner. IL-33 was expressed by a
distinct population of pericryptal fibroblasts in spatial vicinity to
the stem cell niche. IL-33 signaling led to a specific expansion
of cells of the secretory type, including Paneth and goblet cells
by downregulating Notch-signaling pathway. This pathway is
functionally relevant as mice lacking IL-33 showed decreased
Paneth cell (PC) numbers, increased infection, and severe tissue
destruction in response to Salmonella Typhimurium challenge.
RESULTS
IL-33 Provides Protection against the Pathogen
Salmonella Typhimurium
Previous studies have clearly demonstrated the involvement of
the IL-33/ST2 axis in helminth expulsion and neutrophil influx
during sepsis (Alves-Filho et al., 2010; Rostan et al., 2015).
However, although IL-33 is known to be particularly expressed
at barrier tissues such as the gut, its role in the context of bacte-
rial infections remains to be fully determined. To access more
precisely the role of IL-33 in intestinal pathology, we employed
an established Salmonella infection model in IL-33/ and litter-
mate control mice that were backcrossed to homozygosity for
the natural resistance-associated macrophage protein 1
(Nramp1) wild-type alleles (Vidal et al., 1995). Interestingly, after
infection with a virulent Salmonella strain, as compared to IL-
33+/ littermates, IL-33/ mice showed an increased Salmo-
nella burden 5 days postinfection (Figure 1A). This was accom-
panied by increased immune cell infiltration and more-severe
intestinal tissue damage in both caecum and ileum and a striking
loss of PCs in ileum of infected IL-33/ mice (Figures 1B and
1C). Staining with the epithelial marker b-catenin on cecal
cross-sections confirmed areas of almost complete epithelial
loss in IL-33/mice as compared to controls (Figure 1D). Based
on these findings, we speculated that the epithelial antimicrobial
defense might be compromised in mice lacking IL-33. Indeed,
Salmonella-infected IL-33/ mice showed reduced lysozyme
and UEA-1 (Ulex europeus agglutinin-1) staining, markers for
Paneth and goblet cells, respectively (Figure 1E). Paneth and
goblet cells are important secretory epithelial cells with innate
immune functions and defense against enteric pathogens (Lie´-
vin-Le Moal and Servin, 2006). Additionally, in previous studies,
goblet cell depletion in the course of Salmonella infection has
been suggested as a strategy of the pathogen to reside within
the host (Barthel et al., 2003). Our finding was further supported
by qPCR analyses of AMPs produced by PCs such as angioge-
nin 4, defensin a5, cryptidin, and lysozyme, which were also
downregulated in IL-33/ mice as compared to controls (Fig-
ure 1F). Collectively, our data suggest that IL-33 signal transduc-
tion protects from S. Typhimurium infection and promotes(D) Immunohistological staining for the epithelial marker b-catenin on cecal cross
bars represent 100 mm). Graph shows quantification of fluorescence intensity
fluorescence).
(E) Representative pictures of UEA-1 and lysozyme double staining on termina
infection (scale bars represent 50 mm). Graph shows quantification of positive ce
(F) qPCR analysis of the antimicrobial peptides angiogenin-4, defensin a5, cryptidi
values relative to HPRT ± SD).epithelial antimicrobial defense. Notably, 16S-based next gener-
ation sequencing analysis of the intestinal microbiota of IL-33/
and littermate control mice in the steady state revealed no signif-
icant alterations in the microbial composition, ruling out that mi-
crobiota changes in IL-33/ mice account for their increased
susceptibility (Figure S1). We next performed infection experi-
ments using the non-invasive AroAD S. Typhimurium strain that
establishes chronic gut infections in C56BL/6 wild-type mice,
but not significant lethality. Interestingly, compared to unchal-
lenged control mice, infected mice displayed a strong increase
in intestinal IL-33 expression (Figure S2A). Moreover, IL-33/
mice showed higher bacterial burden and increased tissue dam-
age upon Salmonella infection as compared to control mice,
confirming our previous findings that IL-33 is important to control
Salmonella-dependent pathogenesis (Figures S2B and S2C).
Similar to the results obtained with the wild-type (UK-1) strain,
AroAD Salmonella-treated IL-33/ mice showed decreased
numbers of PCs and AMP expression (Figures S2D–S2F).
Indeed, we observed a significant reduction of goblet cells and
lower transcripts of its marker Muc2 in infected IL-33/ mice
as compared to controls (Figures S2G and S2H). Collectively,
these data suggest that IL-33 triggers essential epithelial
changes during danger- or infection-associated challenge to
the host.
IL-33 Induces Specific Expansion of Cells of the
Secretory Lineage in the Small Intestine
To better characterize the role of IL-33-dependent signal trans-
duction in the gut epithelium in vivo, we generated mice condi-
tionally expressing IL-33 in the intestine (IL-33Vcre; Figure 2A).
Histological analysis of the terminal ileum of mice constitutively
expressing IL-33 in the gut indicated the presence of pro-
nounced goblet cell hyperplasia, confirming previous observa-
tions on the role of IL-33 in helminth infection models (Koyasu
and Moro, 2013). Interestingly, more-detailed histological ana-
lyses using H&E and PAS (periodic acid-Schiff) staining demon-
strated that IL-33 overexpression not only led to an increment in
goblet cells but also to significantly increased numbers of PCs
within small intestinal crypts (Figure 2B). Our findings therefore
indicated that IL-33 might have broader functions on epithelial
cells than previously reported. In fact, immunohistochemical
(IHC) staining of UEA-1, lysozyme, and chromogranin A
(ChgA), which serve as gut-specific markers for goblet, Paneth,
and EE cells, respectively, also demonstrated increased
numbers of these cells after IL-33 overexpression. In contrast,
cells of the absorptive lineage were not increased as indicated
by staining for the enterocyte marker alkaline phosphatase
(AP) (Figure 2C). To further confirm the high numbers of secretory
cells in IL-33VCre mice, we analyzed the expression of a panel of
genes preferentially produced by these cell types by qPCR. We-sections from IL-33+/ and IL-33/mice infected with S. Typhimurium (scale
calculated by ImageJ from the b-catenin staining (CTCF, corrected total cell
l ileum cross-sections of IL-33+/ and IL-33/ animals after S. Typhimurium
lls from above stainings (n = 5; mean ± SD).
ns, and lysozyme inSalmonella-treated IL-33+/ and IL-33/mice (n = 5; mean
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Figure 2. Gut-Specific IL-33 Expression Induces Expansion of Secretory-type Intestinal Epithelial Cells
(A) Schematic illustration of the generation of IL-33VCre mice.
(B) Terminal ileum cross-sections of control and IL-33Vcre mice were stained with H&E and PAS (scale bar represents 100 mm). Insets show magnified crypt
areas. Graph shows quantification of PCs present per crypt from above stainings.
(C) Terminal ileum cross-sections from control and IL-33VCre mice stained with UEA-1, lysozyme, chromogranin A (ChgA), and alkaline phosphatase (AP) (scale
bar represents 50 mm).The graph on the right shows quantification of the stainings (n = 3; mean ± SD).
(D) qPCR analysis for PC markers in small intestines of control and IL-33VCre mice (n = 9; mean values relative to HPRT ± SD).
(E) qPCR for markers of other small intestinal cell types: goblet (Muc2); enteroendocrine (ChgA); absorptive enterocyte (Sucrase); and stem cell (Lgr5) in control
and IL-33Vcre mice (n = 9; mean values relative to HPRT ± SD).
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also observed a marked increment in transcripts of the AMPs
Ang4, MMP7, PLA2G2A, and Defa5 in IL-33Vcre mice as
compared to controls (Figure 2D), indicating increased number
of PCs in these mice. Moreover, the markers for goblet and EE
cellsMuc2 and ChgA, respectively, were also significantly upre-
gulated in IL-33Vcre mice as compared to controls (Figure 2E). In
striking contrast, transcripts of Sucrase, a marker for absorptive
enterocytes, and Lgr5, a marker for intestinal stem cells, were
significantly downregulated, indicating that IL-33 affects differ-
entiation rather than proliferation of epithelial progenitors (Fig-
ure 2E). Hence, our analyses showed a marked and specific
IL-33-dependent increment in gut epithelial cell types of the
secretory lineage.
Recently, the role of IL-33 as a signaling molecule has been
discussed in many chronic and auto-immune diseases like
arthritis, liver injury, and multiple sclerosis (Palmer and Gabay,
2011). Hence, our experimental approach did not exclude other
strategies of IL-33 signaling, importantly where the cytokine can
be perceived by the epithelium through external sources as an
alarmin. To investigate the physiological relevance of the cyto-
kine when secreted in a systemic manner and not when it is
restricted to be expressed intracellularly, we employed a strat-
egy to systemically overexpress IL-33 via minicircle DNA
(mcIL-33; Figure S3A). In support of our previous conclusions,
similar abundance of cells of the secretory lineage as in IL-
33Vcre mice was observed in mcIL-33-injected mice by histo-
logical staining (Figure S3B). Quantitative mRNA analyses of
themarkers of these secretory cell types further supported these
findings (Figure S3C). Taken together, our data indicate that in-
testinal epithelial progenitor cells are targets of IL-33, skewing
their differentiation toward secretory IEC, cells with essential
functions in barrier integrity and intestinal homeostasis.
Pericryptal Fibroblasts in the Small Intestine Are the
Primary Source of IL-33 Expression upon Systemic
Infection
Because IL-33 has been reported to be expressed by various cell
types including mast cells, epithelial cells, fibroblasts, and mac-
rophages (Liew et al., 2010; Sponheim et al., 2010), we next
investigated the primary cellular source of intestinal IL-33 by
staining cross-sections from healthy humans and mice guts.
Interestingly, the staining patterns suggested that IL-33 is ex-
pressed specifically in a distinct population of subepithelial cells
neighboring the crypt base. In contrast, no positive signal could
be observed in intestinal epithelial cells (Figure 3A). This finding
was further supported by stainings in IL-33LacZ/LacZ reporter
mice where a marked b-galactosidase activity was also found
in pericryptal cells (Figure 3B). Moreover, double staining for
b-galactosidase and the myofibroblast marker a-smooth muscle
actin (a-SMA) demonstrated co-localization of IL-33 to pericryp-
tal myofibroblasts (Figure 3C). In addition, isolated primary myo-
fibroblasts from IL-33LacZ/LacZ reporter mice stained positive for
X-gal, further confirming our above findings (Figure 3C). Thus,
our data indicate that pericryptal fibroblasts act as a major
source of IL-33 in the steady state gut as opposed to epithelial
localization observed in samples from the skin or stomach
(data not shown). Collectively, these data suggest a cross talk
of pericryptal fibroblasts with epithelial progenitor cells via IL-33.IL-33 has been reported to act in response to cellular stress
including necrosis and infectious challenges (Liu and Turnquist,
2013). Accordingly, peritoneal macrophages upregulate IL-33 at
the mRNA level upon TLR ligand stimulation (Espinassous et al.,
2009). In order to investigate whether pericryptal fibroblasts up-
regulate IL-33 expression in response to microbial challenges,
we intraperitoneally treated C57BL/6 mice with a sub-lethal
dose of lipopolysaccharide (LPS) or fecal bacteria. IL-33 gene
expressionwas strongly induced in the small intestine (Figure 3D)
of LPS-challenged animals. Moreover, stainings of ileal sections
of control, LPS-treated, or septic IL-33LacZ/LacZ reporter mice
demonstrated increased activity of b-galactosidase in crypt sub-
epithelial myofibroblasts (Figure 3E). Quantification of specific
b-galactosidase activity showed increased IL-33 expression in
LPS-treated and septic animals as compared to controls. Our
data indicate that IL-33-mediated signaling from subepithelial
cells to epithelial progenitor cells might be a defensemechanism
by which the organism responds to an infectious challenge at
barrier tissues. IL-33 might therefore serve to translate signals
derived from systemic infections into a local organ-specific
response, which serves to enforce barrier function in order to
reduce further bacterial translocation. To further support this hy-
pothesis, cultured primary myofibroblasts from small intestines
of C57BL/6 mice were stimulated with serum collected from
either control or LPS-treated IL-33/ mice. IL-33 was detected
in the supernatants of fibroblasts by ELISA with significantly
higher concentrations in cultures treated with serum from LPS-
treated animals (Figure 3F) as compared tomock-treated control
serum. IHC stainings of LPS-serum-stimulated primary fibro-
blasts confirmed the presence of IL-33 within the cells (data
not shown).
Systemic infection in humans, as mimicked in our experi-
mental model, is associated with an acute phase response and
the expression of various proinflammatory cytokines including
tumor necrosis factor alpha (TNF-a), IL-6, and IL-1b (Papadakis
and Targan, 2000). Previous studies reported human intestinal
fibroblasts to respond to various proinflammatory cytokines
released during systemic infection (Jobson et al., 1998). We
therefore reasoned whether inflammatory cytokines would also
induce pericryptal fibroblasts from human gut to synthesize IL-
33. Indeed, stimulation of human gut biopsies with inflammatory
cytokines was sufficient to induce IL-33 expression in vitro
(Figure 3G). Moreover, myofibroblasts isolated from human
ileum significantly upregulated IL-33 expression when stimu-
lated with the proinflammatory cytokines TNF-a or IL-1b (Fig-
ure 3H). Finally, IL-33 upregulation in stimulated ileal fibroblasts
could be confirmed at the protein level using immunofluores-
cence staining (Figure 3I). Collectively, our data suggest that
IL-33 can be induced and secreted by subepithelial fibroblasts
in response to microbial challenges in proximity to the stem
cell niche, thereby indicating an important regulatory role of the
cytokine.
IEC-Intrinsic IL-33 Signaling Drives the Expansion of the
Secretory Lineage
Recent studies have shown that IL-33 stimulates the release of
type 2 cytokines like IL-4, IL-13, and IL-5 by various immune
cell types to carry out its biological functions (Yang et al., 2013).Cell Reports 15, 1743–1756, May 24, 2016 1747
Figure 3. Intestinal IL-33 Expression Is Localized to Pericryptal Fibroblasts and Increased in Response to Systemic Infection
(A) Terminal ileum cross-sections from healthy patients and C57BL6 mice stained for IL-33 (scale bar represents 75 mm). Insets showmagnified crypt areas with
positive staining in subepithelial cells.
(B) X-gal staining of terminal ileum sections from untreated IL-33LacZ reporter mice showing b-galactosidase activity at the crypt bottom (scale bar represents
500 mm). The right side picture shows a magnified crypt bottom (scale bar represents 50 mm).
(C) Terminal ileum sections from IL-33LacZ reporter mice stained with anti-aSMA (scale bar represents 100 mm) for myofibroblasts. Next picture shows co-
localization of aSMA and X-gal staining (scale bar represents 100 mm). The last picture shows X-gal staining of a single terminal ileummyofibroblast from a primary
culture (scale bar represents 50 mm). Inset shows negative control.
(D) qPCR analysis of IL-33 expression in the ileum of LPS-treated animals as compared to control C57BL/6 (nine mice per group; relative expression to
HPRT ± SD).
(E) Ileum cross-sections stained with X-gal from control, LPS-challenged, and septic IL-33 reporter mice (scale bar represents 50 mm). Graph depicts quanti-
fication of b-galactosidase activity (n = 6; relative to 1 mg of total protein ± SD).
(F) IL-33 measured via ELISA in supernatants of primary ileal myofibroblasts stimulated with serum from either control or LPS-challenged IL-33/ mice.
(G) Expression levels of IL-33 in human ileal biopsies stimulated with a combination of the inflammatory cytokines TNF-a, IL-6, and IL-1b (n = 8; mean values
relative to HPRT + SD).
(legend continued on next page)
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To investigate whether IL-33 directly or indirectly acts on intesti-
nal epithelial cells, we used a pure epithelial organoid culture sys-
tem in vitro (Figure S4A) as previously described (Sato et al.,
2009). Isolated small intestinal crypts were cultured to epithelial
organoids in the presence or absence of recombinant IL-33. In
agreement with our in vivo studies, a significantly higher number
of PCs per crypt could be observed in cultures treated with IL-33
for 5 days (Figure 4A). This finding was confirmed by qPCR for
markers of secretory cells like Ang4 and Muc2, suggesting a
direct effect of IL-33 on secretory cell expansion. To ultimately
exclude an indirect effect via residual contaminating lymphoid
cells, such as ILC2, in the crypt culture, organoids were grown
from the small intestine of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mice. IL-33-dependent PC expansion in organoids gener-
ated from these mice was indistinguishable from wild-type mice
(Figure 4B). In line with this observation, transcripts of themarker
PLA2G2A were significantly increased in NSG organoid cultures
stimulated with IL-33 in comparison to controls (Figure 4C).
Notably, administration of IL-33 to NSG mice in vivo also
increased the number of PCs and relative expression of Ang4, a
specific marker for this cell type (Figure S4B).
To further exclude a potential role of ILC2, we generated orga-
noids fromRora/mice that are deficient in the differentiation of
these cells (Wong et al., 2012). Again, a significantly higher num-
ber of PCs and increased lysozyme expression was observed
upon IL-33 stimulation, confirming that functional ILC2 is not rele-
vant for this effect (Figure S4C). Finally, to exclude an indirect
effect of IL-33 via autocrine IL-4 and/or IL-13 produced by IEC
or potentially contaminating cells, we generated crypt organoids
fromgut tissueof IL-4Ra/mice,which lacksignalingof the latter
two cytokines. IL-33-treated IL-4Ra/ organoids again showed
increased PC numbers indistinguishable from IL-33-treated
wild-type organoids, indicating that neither IL-4 nor IL-13 was
necessary for this phenomenon and that IL-33 has a direct effect
on epithelial cells within the crypt niche (Figure S4D). Collectively,
our data suggested that IL-33 can directly signal to the intestinal
epithelium, promoting the expansion of secretory IEC.
The ST2 Receptor Is Expressed on Epithelial Progenitor
Cells and Is Essential for IL-33-Induced Secretory Cell
Expansion
The above data indicated that intestinal epithelial cells can
directly respond to extracellular IL-33. To ascertain the expres-
sion of the IL-33 receptor ST2 in IEC, we first stained ileal
cross-sections of healthy humans and unchallenged C57BL/6
mice for ST2. Membranous staining was confirmed throughout
the crypt-villous axis. The specificity of the staining was reaf-
firmed by using corresponding sections from ST2/ mice as
controls (Figure 5A). To validate the above findings, we analyzed
ST2 expression on cultured epithelial cells derived from Lgr5-
eGFP reporter mice, in which stem cells can be traced by GFP
expression. Of note, the expression of ST2 on differentiated
intestinal cells (Lgr5neg) was low whereas stem (LGR5high) and(H) Expression levels of IL-33 in cultured human primary ileal myofibroblasts stim
HPRT + SD).
(I) Representative pictures of primary human ileal myofibroblasts stained for IL-33
cytokines (scale bar represents 50 mm).progenitor (Lgr5int) cells showed high ST2 expression, providing
evidence that stem and progenitor cells can be direct targets of
IL-33 (Figure 5B). Strikingly, no increase in PC counts or expres-
sion of secretory cell markers was observed when small intesti-
nal organoids were generated from ST2/mice and were stim-
ulated with IL-33 (Figures 5C and 5D), indicating that IL-33
signaling functionally depends upon ST2 expression on the crypt
epithelium. Finally, to exclude indirect IL-33 signaling in vivo via
ST2 receptor expressed on hematopoietic cells, we generated
chimeric mice, which received bone marrow cells from either
C57BL/6 or ST2/ mice (Figure S5A). IL-33 expression in
chimeric mice resulted in a comparable secretory cell phenotype
among the two groups. This was confirmed by IHC stainings for
various markers of secretory cells (lysozyme, ChgA, and UEA-1),
which were equally upregulated in IL-33-treated mice that
received wild-type or ST2-deficient BM cells, respectively (Fig-
ure S5B). This was also highlighted by quantitative mRNA anal-
ysis for the PC marker Ang4 and the goblet cell marker Muc2
(Figure S5C). Collectively, our data indicated that ST2 receptor
expression on intestinal epithelial cells is functional and trans-
mits the IL-33 signal into epithelial progenitors in a directmanner.
IL-33 Regulates Intestinal Cell Fate Decisions via
Diminished Notch Signaling
Early expression of key transcription factors (TFs) like Hes1 and
Math1 are known to direct intestinal epithelial differentiation into
the twomajor lineages: the absorptive and the secretory lineage,
respectively (Gazit et al., 2004; Jensen et al., 2000). Because our
model showed a specific increase in cells of the secretory line-
age, we hypothesized that IL-33 might regulate expression of
these differentiation factors. Indeed, we observed an increased
expression of the early differentiation markers Math1, Sox9,
and Ngn3 and, at the same time, a lower expression of Hes1 in
IL-33VCre mice when compared to controls (Figure 6A). Similar
results were obtained when IL-33 was expressed systemically
(data not shown). The latter finding was confirmed by Hes1 im-
munostaining showing abundant Hes1 protein expression in en-
terocytes and CBCs in control mice whereas, in IL-33VCre mice,
expression was significantly downregulated (Figure 6B). Collec-
tively, our data indicate that IL-33 signaling directly affects cell
fate decisions at very early stages of intestinal epithelial cell
fate determination.
Recent studies have provided evidence for a major role of
the Notch-signaling pathway in determining intestinal cell fate
decisions and expression of the respective master TFs (Noah
and Shroyer, 2013). Notch signaling is activated when a signal-
receiving cell bearing the Notch receptor binds to Delta (Dll1
and -4) or Jagged (Jag1 and -4) transmembrane proteins on
the signal-sending cell. The receptor-ligand complex when acti-
vated is cleaved by the g-secretase complex, resulting in the
release of the Notch intracellular domain (NICD), which then
can regulate gene expression as part of TF complexes in the
nucleus. Because Notch signaling has been demonstrated toulated with TNF-a, IL-6, IL-1b, or in combination (n = 3; mean values relative to
(green), phalloidin (red), and Hoechst (blue) after stimulation with inflammatory
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Figure 4. IL-33 Drives Intestinal Epithelial Cell Responses in a Direct Manner Independent of ILC2
(A) Representative pictures of small intestinal crypt organoids of C57BL/6 mice (scale bar represents 100 mm) stimulated with IL-33 over a period of 5 days. PC
granules are stained with Zinpyr-1 (ZP-1). Arrows indicate PCs. Insets show single crypts from organoids bearing PCs at higher magnification. First graph depicts
quantification of PCs from the above experiment (n = 30; mean values ± SD) and second graph depicts real-time analyses for secretory cell markers (Ang4 and
Muc2) from control and IL-33-stimulated small intestinal crypt organoids (n = 9; mean values relative to HPRT ± SD).
(B) Representative pictures of small intestinal crypt organoids from NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) stimulated with IL-33 over a period of 5 days (scale
bar represents 100 mm). Secretory cells are stained with UEA-1 (scale bar represents 100 mm). Graph shows UEA-1+ cells per organoid bud (n = 45; mean ± SD).
(C) qPCR analysis of the antimicrobial peptide PLA2G2A from control and IL-33-stimulated NSG-derived organoids (n = 3; mean values relative to HPRT ± SD).promote expression of Hes family genes and to repress expres-
sion of Math1 (Tsai et al., 2014), we reasoned that IL-33 might
program epithelial differentiation by regulating Notch signaling.
Notably, IHC staining of NICD1 on ileal sections of control and
IL-33VCre mice showed marked differences at crypt bottom
cells. Accordingly, NICD1was detected in the cytoplasm of crypt
epithelial cells in control mice whereas, in IL-33VCre mice,
NICD1 was mostly downregulated, indicating impaired Notch
signaling in the presence of IL-33 (Figure 6B). Moreover, expres-
sion of the notch ligand Dll4 known to be present exclusively on
cells of the secretory lineage (Sato et al., 2011) was markedly
decreased in IHC stainings of ileum sections in IL-33Vcre mice
as compared to controls (Figure 6B). The above findings were
further supported by western blot analysis showing decreased
intensity for both NICD1 and Dll4 in IEC (Figure 6C). Finally,
qPCR analyses showed lower expression of the Notch
ligands Dll1, Dll4, and Jag1 in IL-33VCre mice (Figure 6D)
whereas Jag2 expression was unaltered (data not shown).
We also evaluated whether Notch ligands are also suppressed
in Salmonella-infected animals. As expected, Dll1 and Dll41750 Cell Reports 15, 1743–1756, May 24, 2016were downregulated in controls infected with Salmonella as
compared to uninfected controls. However, this was not
observed in infected IL-33/ animals (Figure S6). To investigate
whether Notch signaling was functionally involved in the epithe-
lial response toward IL-33, we generated crypt organoids from
C57BL/6 mice and stimulated them with IL-33 with or without
addition of the Notch ligand Jagged-1 or the Notch inhibitor
N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester (DAPT). Whereas organoids treated with either IL-33 or
DAPT developedmore PCs as demonstrated above, the addition
of Jagged-1 completely blocked IL-33-induced expansion of
PCs and decreased expression of the secretory cell markers
Ang4 (Figures 6E and 6F). Collectively, our data demonstrate a
role of IL-33-balanced Notch signaling in promoting the reprog-
ramming of intestinal epithelial differentiation.
DISCUSSION
The prevailing information regarding IL-33 in the intestine has
focused its role either as a mediator of type 2 ILC, as an alarmin,
Figure 5. ST2 Is Highly Expressed on Epithelial Stem and Progenitor Cells and Is Essential for IL-33 Signal Transduction
(A) Terminal ileum cross-sections from healthy humans and C57BL/6 mice were stained for ST2 (red), Hoechst (blue), and UEA-1 (green; scale bars represent
100 mm and 75 mm). Highlighted sections show magnified villi and crypts with positive staining at crypt epithelial cells (scale bars represent 25 and 20 mm,
respectively).
(B) FACS analysis of ST2 expression on intestinal epithelial cells derived from organoids. Upper panel shows the gating strategy in control and Lgr5-eGFP mice.
Lower panel shows expression of ST2 gated on different Lgr5 populations.
(legend continued on next page)
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or as an activator of the nuclear factor kB (NF-kB) pathway, sug-
gesting broad functions in immune defense (Seidelin et al.,
2011). Moreover, recent publications have highlighted the role
of IL-33 in establishing T-reg cells and indicated TH1 effector
cells as cellular target of the cytokine (Schiering et al., 2014;
Turnquist et al., 2011). Using various experimental approaches,
we now provide evidence that, in the small intestine, IL-33
expression is confined to a distinct population of subepithelial
myofibroblasts: (1) IL-33 reporter gene activity as well as IL-33
immunostaining was restricted to a population of spindle-like
and a-sma+ cells directly underneath the epithelium and (2) iso-
lated myofibroblasts from the small intestine of animals and hu-
mans expressed and released IL-33 in vitro. In contrast to a pre-
viously published study in a model of intestinal mucositis by
treatment of a chemotherapeutic agent, we were not able to
confirm epithelial IL-33 expression in the small intestine (Guabir-
aba et al., 2014). Hence, we speculate that IL-33 expression and
secretion might be differentially regulated based on danger sig-
nals received. Although, our data indicate a specific function of
pericryptal fibroblast released IL-33 in the small intestine, we
do not rule out other sources of IL-33, which might be relevant
in certain tissues and under certain circumstances.
IL-33 expression and secretion by pericryptal fibroblasts was
significantly increased as a response tomicrobial challenges and
proinflammatory cytokines like TNF-a and IL-1b in both mouse
and human. Thus, pericryptal fibroblasts, underneath the crypt
base, might serve as mucosal sensors of local or systemic infec-
tions, translating danger signals to neighboring cells by releasing
IL-33, which can directly induce epithelial progenitor cells to
differentiate into specific epithelial subtypes. Indeed, forced
expression of IL-33 within the gut epithelium led to selective dif-
ferentiation of epithelial progenitors to cells of the secretory type
(Paneth, goblet, and EE cells), cell types with important functions
in innate immune and tissue defense. Importantly, similar find-
ings were obtained when IL-33 was expressed in a gut extrinsic
way, excluding the possibility that IL-33 acted epithelial cell
intrinsically to affect progenitor cell differentiation. ILC2s have
previously been shown to be major responders to IL-33 and
have been demonstrated to promote secretory cell hyperplasia
like goblet and tuft cells (Moro et al., 2010; von Moltke et al.,
2016). However, our experimental evidence supports a direct
IEC response toward extrinsic IL-33: (1) intestinal epithelial orga-
noids, devoid of contaminating cells, responded to extrinsic
stimulation of IL-33; (2) ST2/ intestinal epithelial organoids
were unable to promote secretory IEC differentiation; and (3)
IL-4Ra, NSG-, and Rora-deficient organoids responded to IL-
33 comparably to wild-type organoids, ruling out indirect epithe-
lial activation via lymphoid cells such as ILC2 or their related cy-
tokines. However, our data do not rule out the possibility that,
in vivo, the epithelial response by IL-33 might be further sup-
ported by IL-33 signaling into lamina propria cells. Chimeric
C57BL/6 mice reconstituted with ST2/ bone marrow cells(C) Representative pictures of small intestinal crypt organoids of control and IL
granules are stainedwith fluorescent ZP-1. Insets showmagnified buds of organoi
per organoid (n = 50; mean ± SD).
(D) qPCR analysis of antimicrobial peptides from control and IL-33-stimulated or
1752 Cell Reports 15, 1743–1756, May 24, 2016showed partial impairment of secretory cell expansion following
IL-33 expression. Hence, it is possible that, along with IL-33,
lamina propria cells like ILC2s can contribute to epithelial differ-
entiation and barrier maintenance.
FACS analysis of isolated epithelium from Lgr5-eGFP ileum
crypt organoids showed co-localization of the ST2 receptor
with the stem cell marker LGR5, suggesting that stem and pro-
genitor cells aremajor targets of IL-33 in the intestinal epithelium.
This conclusion is in line with our finding of differential Notch
signaling and expression of TFs known to drive the differentiation
of secretory IEC from intestinal epithelial progenitor cells.
Although, it cannot be fully ruled out that LGR5- cells can be tar-
geted by IL-33. Indeed, to directly attribute IL-33 signaling via in-
testinal stem cells, advanced mouse models with conditional
deletion of ST2 in stem cell compartment are necessary.
Many parallel signaling pathways have been studied in the
context of IL-33 functionality like MyD88, MAPK, and ERK
signaling (Martin, 2013). Our data indicated an effect of IL-33
on early cell fate markers, as expression for Hes1 was downre-
gulated and Math1 was significantly upregulated. Several
studies have reported major signaling pathways like Wnt and
Notch to direct stem cells into differentiation of these secretory
cells (Tian et al., 2015). Accordingly, NICD, which functions as
a TF for Hes1 (Tsai et al., 2014), was downregulated in an IL-
33-proficient system. In agreement with these findings, IL-33
diminished Notch signaling in vivo and in vitro and forced Notch
activation blocked IL-33-induced Paneth and goblet cell expan-
sion in organoid cultures. Moreover, ablation of Notch activity in
epithelial organoids by using a g-secretase inhibitor mimicked
IL-33-induced Paneth and goblet cell expansion. These data
pointed toward an impairment of Notch signaling on the level
of receptor-ligand interaction. In agreement with these previous
reports, expression of Dll1 and Dll4 transcripts by Paneth and
goblet cells (Shimizu et al., 2014) were suppressed by IL-33 stim-
ulation. Taken together, our data indicate that IL-33-induced
secretory cell hyperplasia occurs in a manner that is dependent
upon Notch inhibition.
Previous studies have citied the imbalance of IL-33/ST2 axis in
various infectious diseases like Leishmania major, Toxoplasma
gondii, Mycobacterium tuberculosis, and Schistosoma mansoni
(Rostan et al., 2015). Our data show compelling evidence of
IL-33-induced secretory cell expansion, eventually resulting in
copious amount of AMPs as a response to Salmonella infection.
This phenomenon could give leverage in Salmonella-induced gut
barrier disruption as IL-33/ mice showed higher susceptibility
to infection and severe gut tissue destruction in both an acute
and chronic model of Salmonellosis. Expression of many essen-
tial AMPs including Defensin a5, a crucial factor for expelling
pathogenic bacteria (Ouellette, 2011), was impaired in infected
IL-33/ mice, a finding that potentially contributes to their sus-
ceptibility. However, once the epithelial barrier is overcome by
bacteria, type 2 immunity mediated by ILC2 or Th2 cells, which-33-stimulated cultures from ST2/ mice (scale bar represents 100 mm). PC
d-bearing PC. Arrows indicate PC. Graphs depict quantification of PC numbers
ganoids derived from ST2/mice (n = 9; mean values relative to HPRT ± SD).
Figure 6. IL-33 Interferes with the Notch-Signaling Pathway and Expression of Master Regulators of Intestinal Epithelial Cell Differentiation
(A) qPCR analysis of early differentiation marker genesMath1,Ngn3, Sox9, andHes1 (n = 9; mean values relative to HPRT ± SD) from control and IL-33VCremice.
(B) IHC staining for Hes1, NICD1, and Dll4 on terminal ileum sections of control and IL-33VCre mice (scale bar represents 50 mm). Graph depicts quantification of
Hes-1-, NICD1-, and Dll4-positive cells from above staining (n = 3; mean ± SD).
(C) Western blot analysis of NICD1 and Dll4 expression in IEC lysates from control and IL-33VCre mice. The housekeeping gene b-actin was used as loading
control.
(legend continued on next page)
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are IL-33 dependent, might be important in eradication of the
pathogen.
In summary, our data show an unexpected role of IL-33 in the
reprogramming of intestinal epithelial progenitor cells into cells
of the secretory IEC lineage, cells with important innate immune
functions. Our data indicate that pericryptal fibroblast are sen-
sors of local and systemic infection, and their release of IL-33
can serve to translate these signals into a physiologic response
to enforce barrier function in an effort to impede further microbial
invasion.
EXPERIMENTAL PROCEDURES
Mice
Mice carrying a loxp-flanked GFP Stop cassette upstream of an IL-33 trans-
gene (McHedlidze et al., 2013) were crossed with Villin-creERT2 mice to
generate inducible gut-specific IL-33 transgenic mice (IL-33Vcre). Genotyping
was performed by PCR on tail DNA. For induction of constitutive expression of
IL-33 in the gut, micewere once injected intraperitoneally with 200 ml tamoxifen
(5 mg/ml in ethanol; Sigma). To induce systemic release of soluble IL-33, hy-
drodynamic tail vein injection was performed using aminicircle-based plasmid
vector containing IL-33 expression cassettes (mcIL-33). ST2/ mice were
described recently (McHedlidze et al., 2013). IL-33LacZ/LacZ reporter mice
(C57BL/6 background) were generated as described previously (Skarnes
et al., 2011). For some experiments, this strain was used after backcrossing
to mice harboring an Nramp1G169 wild-type allele to overcome the Nramp1
deficiency of C57/Bl6 mice as previously described (Loomis et al., 2014). For
the generation of bone marrow chimeras, 13 107 cells from femurs and tibias
of donor mice (C57BL/6 or ST2/) were intravenously injected into lethally
irradiated (10 Gy) recipient mice. Mice were let to recover for 8 weeks followed
by mcIL-33 injection into the tail veins. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG), IL-4Ra/, and Lgr5-EGFP-IRES-creERT2 mice were obtained from
Jackson Laboratory. Rorasg/sg (Roratm1a(EUCOMM)Wtsi) were from EUCOMM.
Animal experiments were approved by the governments of Rheinland-Pfalz
and Mittelfranken.
Salmonella Typhimurium Infection
The Salmonella Typhimurium strain AroAD (Grassl et al., 2008) and biolumines-
cent UK-1 (Riedel et al., 2007) were routinely cultured in Luria-Bertani broth at
37C with aeration and continuous shaking at 225 rpm with appropriate anti-
biotics. Mice were orally gavaged with 20 mg streptomycin 24 hr prior to infec-
tion. Food was removed for 8 hr before infection, after which mice were orally
gavagedwith13 106 colony-forming unit (CFU). Bacterial burden wasmoni-
tored via IVIS Lumia II or plating of stool. Mice were sacrificed via CO2 inhala-
tion at indicated time points, and tissues were harvested for microscopy, his-
tology, RNA extraction, and analysis of bacterial translocation.
Experimental Models of Septic Shock and Poly-microbial Sepsis
Mice were injected intraperitoneally with LPS (2.5 mg/kg body weight; Sigma-
Aldrich) or stool suspensions from C57BL/6 mice. Viability was monitored by
visual examination and by measuring body temperature and weight loss.
Mice were sacrificed after 6–8 hr of injection.
Human Samples
Terminal ileum biopsies were collected from the endoscopy unit of the Univer-
sity Clinic Erlangen. The specimens were obtained during routine diagnostics
procedures and immediately processed for stimulation with human cytokines
TNF-a (100 ng/ml; Invitrogen), IL-1b (10 ng/ml; Sigma), and IL-6 (10 ng/ml; Life
Technologies). The collection of samples was approved by the local ethical(D) Expression levels of Notch ligands Dll1, Dll4, and Jagged-1 in control and IL-
(E) Representative pictures of in-vitro-cultured crypt organoids from C57BL/6 m
represents 100 mm). Insets show magnified crypt-bearing PCs.
(F) Quantification of PCs/crypt (+SD) and real-times analysis for Ang4 from abov
1754 Cell Reports 15, 1743–1756, May 24, 2016committee and the institutional review board of the University of Erlangen-Nur-
emberg with each patient giving their written informed consent.
Primary Myofibroblast Culture
Murine terminal ileum myofibroblasts were isolated and cultured as described
previously (Lawrance et al., 2001). More details can be found in the Supple-
mental Experimental Procedures.
Histology, Immunohistochemistry, and LacZ Staining
Histopathological analyses were done with formalin-fixed paraffin-embedded
tissue sections. After H&E and PAS staining, the sections were subjected to
IHC staining using the TSA Cy3 (PerkinElmer) system for fluorescence or by
addition of a diaminobenzidine (DAB) substrate (ABC staining kit; Santa Cruz
Biotechnology) as recommended by the manufacturer. LacZ staining was per-
formed by incubating frozen cryosections in X-gal solution O/N at 37 followed
by nuclear staining using fast red solution. The sections were analyzed using
fluorescence microscopy (Leica CTR6000) and confocal microscopy (Leica
TCS SP5). A list of antibodies can be found in the Supplemental Experimental
Procedures.
Crypt Isolation and Organoid Culture
Crypts were isolated from small intestines of 8- to 12-week-old mice and
cultured for a minimum of 6 days as described previously (Sato et al., 2009).
More details can be found in the Supplemental Experimental Procedures.
Flow Cytometry of LGR5-Positive Stem Cells
Intestinal crypts of LGR5-EGFP-IRES-CreERT2mice (Barker et al., 2007) were
isolated and cultured as described above and elsewhere (Jung et al., 2011).
More details can be found in the Supplemental Experimental Procedures.
IEC Isolation and Immunoblotting
IECs were isolated and processed as described before (Martini et al., 2016).
More details can be found in the Supplemental Experimental Procedures.
Gene Expression Analysis
Total RNA was extracted from whole-gut pieces, organoids, or isolated IECs
using a RNA isolation kit (Nucleospin II; Machery Nagel). cDNA was synthe-
sized by reverse transcription (iScript cDNA synthesis kit; Bio-Rad). Real-
time PCR was performed using specific QIAGEN Quantitect primer assays.
All experiments were normalized to the housekeeping gene HPRT.
ELISA and b-gal Assay
IL-33 production was measured by the specific Duoset ELISA kit from R&D
systems according to manufacturer’s instructions. Absorbance was read at
450 nm by a Tecan infinite M200 microplate reader. Specific activity of
b-galactosidase in IL-33LacZ reporter mice was measured using the b-gal
assay kit (Invitrogen) following the manufacturer’s protocol.
Statistical Analysis
Data were analyzed by Student’s t test using Microsoft Excel and Graphpad
Prism. Significance levels are indicated as *p < 0.05, **p < 0.01, and ***p <
0.001. All data are presented as mean values ± SD. ImageJ was used to
perform statistics for IHC stainings. Investigators were blinded during data
collection to eliminate potential bias during analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.04.049.33VCre mice (n = 9; mean values relative to HPRT + SD).
ice treated with recombinant IL-33, Jag-1, or Notch Inhibitor (DAPT; scale bar
e experiment (n = 3; relative to HPRT ± SD).
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